To better assess the efficacy and safety profile of COX-2 inhibitors combined with anticancer therapy for patients with NSCLC, the first meta-analysis of data from published randomized controlled trials (RCTs) in this field was performed. The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.